ascopubs.org

Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC).

A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4. Background: CD4+ regulatory T cells (Tregs) ...
EurekAlert!

New antibody selectively targets immune cells that suppress anti-tumor responses

“Taken together, our studies suggest that 2B010 represents an anti-CD25 mAb with unique properties in that it deleted Treg from an inflammatory environment (GVHD) as well as from the TME” “Taken ...
Nature

Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine–phenotype study

Forty six patients with SM were eligible for this study, based upon availability of plasma samples; 23 patients (50%) had ISM, 8 (17%) ASM and 15 (33%) SM-AHNMD. Detailed demographic, clinical and ...
ascopubs.org

Monitoring of the CD3+CD8+/CD4+CD25+FoxP3+ ratio in PBMC in colorectal chemotherapy patients.

Pathologic indicators of chemotherapy response in colorectal liver metastases: A comparative study. Sequential treatment strategy for metastatic colorectal cancer: A phase III study of chemotherapy ...
BioWorld

Invenra announces preclinical data on INV-322, bispecific antibody targeting CTLA-4 and CD25

Invenra Inc. has announced preclinical data supporting the ongoing development of INV-322, a Sniper bispecific antibody co-targeting CTLA-4 and CD25 for cancer developed using Invenra's B-Body ...